CytoDyn Announces Management Update Conference Call on Thursday, August 23
LUTZ, Fla., Aug. 21, 2012 (GLOBE NEWSWIRE) -- CytoDyn Inc. (the "Company") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, and other antibody applications, announced today that it will conduct a management update conference call at 1:00pm ET on Thursday, August 23rd.
The Company will provide an update on their general operations including the recently announced management changes. CytoDyn's management will also provide an update on its agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140.
Date: August 23, 2012
Time: 1:00 PM ET
Toll-free: (877) 303-3199
International: (253) 237-1247
Listen via Internet: http://www.cytodyn.com or
An audio replay will be available for one week at (800) 585-8367 or (404) 537-3406. The conference ID for the replay is 23499213.
About the Company
The Company is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. The Company's proprietary drug candidate Cytolin® is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. The Company intends to explore the clinical development of Cytolin® for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. The Company recently completed a humanized antibody construct of Cytolin®, filed a provisional patent for its use, and manufacturing discussions are underway. In addition, the Company is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. The Company recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin®, CytoFeline™ and the Company please go to www.cytodyn.com.
This press release includes forward-looking statements and includes forward-looking information within the meaning of United States securities laws. These statements and this information represent the Company's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond the Company's control. These factors could cause actual results to differ materially from such forward-looking statements or forward-looking information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or on this forward-looking information.
CONTACT: The Company Richard Trauger Managing Director of Science (760) 522-3869 The Trout Group Senior Vice President Brian Korb, 646-378-2923 email@example.comSource: CytoDyn, Inc.
Released August 21, 2012